KURA Revenue second quarter 2026 Y/Y Growth Comment
Kura Oncology Inc achieved in the second quarter 2026, above Company average Revenue growth of 36.52% year on year, to $ 20.87 millions.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue growth. While Kura Oncology Inc ' s Revenue rise of 36.52% ranks overall at the positon no. 618 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Kura Oncology Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
72.73 %
-5 %
-100 %
(Sep 30 2015)
KURA's II. Quarter Q/Q Revenue Comment
Kura Oncology Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 14.25%, to $ 20.87 millions, from $18.27 millions in the first quarter. KURA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Kura Oncology Inc 's Revenue growth quarter on quarter, overall rank is 650.
Kura Oncology Inc achieved in the II. Quarter 2026 above company average sequential Revenue rise of 14.25%, to $ 20.87 millions, from $18.27 millions in the first quarter. KURA is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.
Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Kura Oncology Inc 's Revenue growth quarter on quarter, overall rank is 650.
Kura Oncology Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 77.23
$ 71.64
$ 67.48
$ 104.03
$ 0.00
Y / Y Revenue Growth (TTM)
-
-
-
-
-
Year on Year Revenue Growth Overall
Ranking
#
#
#
#
#
Seqeuential Revenue Change (TTM)
7.8 %
6.16 %
-35.13 %
-
-
Seq. Revenue Growth (TTM) Overall
Ranking
# 3490
# 2982
# 2305
# 0
# 0
Cumulative Revenue growth Comment
Kura Oncology Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 36.52% year on year, to $ 77 millions if the fiscal year would have ended in Jun 30 2026. Kura Oncology Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Kura Oncology Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Mar 31 2026 rise was beneth at 7.8 % from $71.64 millions achieved in the period from Mar 31 2026 to Jun 30 2025. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.8 % increase from $71.64 millions in the period from Mar 31 2026 to Jun 30 2025.
Kura Oncology Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
Kura Oncology Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 36.52% year on year, to $ 77 millions if the fiscal year would have ended in Jun 30 2026. Kura Oncology Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Mar 31 2026. And, Kura Oncology Inc realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Mar 31 2026 rise was beneth at 7.8 % from $71.64 millions achieved in the period from Mar 31 2026 to Jun 30 2025. Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%. The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 7.8 % increase from $71.64 millions in the period from Mar 31 2026 to Jun 30 2025.
Kura Oncology Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
About Kura Oncology Inc Revenue Growth Rates (KURA), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
63.27%